Biopool gains nucleic acid technology in Xtrana merger
This article was originally published in Clinica
Executive Summary
Biopool International and Xtrana have signed a letter of intent to merge, giving Biopool, which makes haemostasis diagnostic tests, access to Xtrana's proprietary nucleic acid technologies.